Fera Pharmaceuticals announces the acquisition of an investigational new drug to treat fungal otitis externa (FOE).
“This acquisition fulfills a key strategic imperative for Fera—product development and commercialization in specialty and underserved therapeutic categories”
In a Phase 2 pilot study, Itraconazole topical suspension was shown to be effective in the treatment of FOE with no adverse events reported. In addition, the drug has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA).
"This acquisition fulfills a key strategic imperative for Fera—product development and commercialization in specialty and underserved therapeutic categories" says Frank J. DellaFera, President of Fera.
The company is working to complete clinical development required to obtain FDA approval.
Urine RNA analysis shows promise for detecting genitourinary diseases